A Phase 1 Randomized, Double‐Blind, Placebo‐Controlled Single and Multiple Ascending Dose Study of DISC‐3405, a Novel Recombinant Humanized Monoclonal Antibody Targeting TMPRSS6, in Adult Healthy Volunteers

Documenti analoghi

• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses and Dose Titration of Bexicaserin in Healthy Participants in a Randomized, Double‐Blind, Placebo‐Controlled Study
  di: Jonathan Williams, et al.
  Pubblicazione: (2025)
• Phase 1, Single‐Center, Double‐Blind, Randomized, Placebo‐Controlled Studies of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of the Sirtuin 6 Activator SP‐624 in Healthy Adults
  di: Greg Rigdon, et al.
  Pubblicazione: (2024)
• A Phase 1, Randomized, Placebo‐Controlled, Multiple‐Dose, Double‐Blind Study to Evaluate and Compare the Pharmacokinetics and Safety of Rimegepant in Healthy Adult Japanese and Caucasian Individuals
  di: Rajinder Bhardwaj, et al.
  Pubblicazione: (2025)
• A Phase 1, Randomized, Double‐Blind, Placebo‐Controlled, Single Ascending Dose Trial of AWZ1066S, an Anti‐Wolbachia Candidate Macrofilaricide
  di: Graham Devereux, et al.
  Pubblicazione: (2024)
• Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Bexicaserin in Healthy Participants: A First‐in‐Human Randomized, Double‐Blind, Placebo‐Controlled Single Ascending Dose Escalation Phase 1 Study
  di: Rosa Chan, et al.
  Pubblicazione: (2025)